InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Turn Therapeutics Inc.

TTRX Clue Score42
United States Fiscal year ends December CIK 0002023016
$12.00 +5.36% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $12.00 +30.43% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 8 Oct 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2024Operating income−1.8Net income−1.8EPS, diluted−0.07Fiscal year 2025Operating income−5.9Net income−3.2EPS, diluted−0.12
FY2024FY2025
Operating income −1.8 −5.9
Net income −1.8 −3.2
Growth
EPS, diluted −0.07 −0.12
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2024Operating cash flow−1.4Fiscal year 2025Operating cash flow−2.6
FY2024FY2025
Operating cash flow −1.4 −2.6

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2024Cash0.5Shareholders’ equity−0.2Fiscal year 2025Cash4.0Shareholders’ equity4.7
FY2024FY2025
Cash 0.5 4.0
Shareholders’ equity −0.2 4.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
0.2 0.3
1.6 5.6
−1.8 −5.9
Growth
−1.8 −3.2
Growth
Per share
−0.07 −0.12
−0.07 −0.12
Growth
26.6 27.7
26.6 27.7
Growth +4.0%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 2 of 2 years on file.